China Digest: Sequoia backs Neurophth; TransThera bags over $50m

Wuhan Neurophth Biological Technology has secured 400 million yuan ($62 million) in a Series B round of financing jointly led by Guofang FOF and InnoVision Capital, while Nanjing TransThera Biosciences has garnered over $50 million led by Co-Stone Asset Management.